Summary Points
- Scientists developed HOBIT, a tiny implantable device that continuously produces medicines inside the body by integrating engineered cells with oxygen-generation technology.
- The device shields the cells from the immune system, provides a steady oxygen supply, and supports high cell densities, enabling sustained multi-drug delivery.
- Tested in rats, HOBIT maintained stable levels of multiple biologics for 30 days, outperforming non-oxygenated devices which saw rapid decline.
- Future work aims to test larger models and develop disease-specific therapies, advancing toward programmable internal drug factories for chronic condition treatment.
Innovative “Living Pharmacies” Offer Continuous Medication
Scientists are making exciting progress with tiny, implantable devices that act like “living pharmacies.” These devices, tested in rats, contain specially engineered cells that produce medicines right inside the body. Called HOBIT, the device is about the size of a stick of gum and combines cells, oxygen-producing technology, and electronics. Its goal is to treat chronic illnesses without patients needing to remember to take pills or injections. Instead, the device works silently, providing steady doses of multiple medicines over several weeks. This approach could transform how doctors manage long-term health conditions, making treatment simpler and more reliable.
How Technology Supports Better Disease Treatment
The secret behind HOBIT’s success lies in its ability to keep cells alive and active. Engineers designed it to supply oxygen directly where the cells are housed, overcoming a common challenge in implantable devices. In earlier studies, they used a tiny electrochemical part that generates oxygen by splitting water molecules. Now, they combined this oxygen source into a wireless, fully implantable system. The device contains three main parts: a chamber for the cells, an oxygen generator, and electronics to manage oxygen flow and relay data wirelessly. This design allows the cells to produce higher amounts of medicines continuously, even in low-oxygen conditions. Tests showed the device could sustain levels of three different drugs for up to 30 days. Most importantly, the cells inside the device remained alive much longer than in non-oxygenated versions. These advancements make the idea of inside-the-body drug factories more feasible, paving the way for future therapies that are more efficient and less invasive.
Expand Your Tech Knowledge
Learn how the Internet of Things (IoT) is transforming everyday life.
Learn more about cutting-edge innovations supported by the National Science Foundation (NSF).
Sci-BioV1
